No evidence of significant cross-reactivity between the dengue virus (DENV) and SARS-CoV-2 IgG antibodies
No evidence of significant cross-reactivity between the dengue virus (DENV) and SARS-CoV-2 IgG antibodies
Abstract BackgroundSeveral studies reported serological cross-reaction between DENV and SARS-CoV-2 IgG antibodies using rapid point of care (POC) assays. Limited data are available about cross-reactivity when testing is done using advanced chemiluminescence immunoassay (CLIA) and ELISA assays. ObjectiveThis study aims to investigate potential serological cross-reactivity between SARS-CoV-2-IgG and DENV-IgG using CLIA and ELISA assays. Study-designA total of 90 DENV-IgG-ELISA positive and 90 negative pre-pandemic sera were tested for anti-SARS-CoV-2-IgG using the automated CL-900i CLIA assay. Furthermore, a total of 91 SARS-CoV-2-IgG-CLIA positive and 91 negative post-pandemic sera were tested for anti-DENV-IgG using the Novalis ELISA assay. ResultsThe DENV-IgG positive sera had 5 positives and 85 negatives for SARS-CoV-2-IgG. The DENV-IgG negative sera also had 5 positives and 85 negatives for SARS-CoV-2-IgG. No statistically significant difference in specificity between the DENV-IgG positive and DENV-IgG negative sera was found (p-value=1.00). The SARS-CoV-2-IgG positive sera had 43 positives, 47 negatives, and 1 equivocal for DENV-IgG. The SARS-CoV-2-IgG negative sera had 50 positives, 40 negatives, and 1 equivocal for DENV-IgG. No statistically significant difference in the proportion that is DENV-IgG positive between the SARS-CoV-2-IgG positive and SARS-CoV-2-IgG negative sera (p-value=0.58). ConclusionsNo evidence for cross-reactivity between the DENV and SARS-CoV-2 IgG antibodies was found.
Nasrallah Gheyath K.、Shurrab Farah M.、Al-Absi Enas S.、Qotba Hamda、Al-Sadeq Duaa W.、Humaira Fatima、Yassine Hadi. M.、Abu-Raddad Laith J.
Biomedical Research Center, Qatar University||Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar UniversityBiomedical Research Center, Qatar UniversityBiomedical Research Center, Qatar UniversityDepartment of Clinical Research, Primary Health Care CentersBiomedical Research Center, Qatar University||College of Medicine, Member of QU Health, Qatar UniversityBiomedical Research Center, Qatar UniversityBiomedical Research Center, Qatar University||Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar UniversityInfectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation ¨C Education City||World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine¨CQatar, Cornell University, Qatar Foundation ¨C Education City||Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell University
医学研究方法基础医学
Cross-reactionDengueSARS-COV-2CLIAELISA
Nasrallah Gheyath K.,Shurrab Farah M.,Al-Absi Enas S.,Qotba Hamda,Al-Sadeq Duaa W.,Humaira Fatima,Yassine Hadi. M.,Abu-Raddad Laith J..No evidence of significant cross-reactivity between the dengue virus (DENV) and SARS-CoV-2 IgG antibodies[EB/OL].(2025-03-28)[2025-08-02].https://www.medrxiv.org/content/10.1101/2021.04.19.21255725.点此复制
评论